Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment

Launched by UNIVERSITY OF DUBLIN, TRINITY COLLEGE · Mar 16, 2022

Keywords

ClinConnect Summary

The clinical trial titled "Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment" is investigating a new way to help improve memory in people with mild cognitive impairment (MCI), a condition that can lead to more serious memory problems. In this study, 100 participants diagnosed with a specific type of MCI will receive a non-invasive procedure that uses electrical stimulation. They will be divided into four groups: one will receive the active treatment, while the others will receive different types of control stimulation to ensure the results are accurate and not just due to the sensation of stimulation. Researchers will measure how well participants remember words right after treatment and again after a week and 28 days.

To join the study, participants must be at least 50 years old and have a specific level of cognitive ability, but they must not have certain other types of dementia or brain injuries. During the trial, participants can expect to attend a session where they will receive the stimulation and complete a word memory task. Their brain activity will also be monitored to see if there are any changes. This study is currently recruiting, and participation is a chance to contribute to research that could lead to better memory treatments for older adults.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥50 years
• • Diagnosis of probable aMCI or mild AD
• • Montreal Cognitive Assessment between 18-25
• • Mini Mental State Examination score \>21
• • Stable AChl medication \>3 months
• • Adequate visual and auditory acuity
• • Capacity to understand and sign informed consent
• Exclusion Criteria:
• • Any cause of cognitive decline or dementia that is not Alzheimer's disease related including parkinsonism related dementias, vascular dementia, fronto-temporal dementia.
• • Enrolment in an ongoing investigational medicinal product study
• • History in the past 2 years of epileptic seizures
• • Any current major psychiatric disorder
• • Evidence of brain damage, including significant trauma, stroke, hydrocephalus, intellectual disability, or serious neurological disorder.
• • History of alcoholism or drug abuse within the last 12 months
• • Medical devices not eligible for MRI scanning